Ongoing Clinical Trials of Human Immunodeficiency Virus Latency-Reversing and Immunomodulatory Agents

@inproceedings{Delagrverie2016OngoingCT,
  title={Ongoing Clinical Trials of Human Immunodeficiency Virus Latency-Reversing and Immunomodulatory Agents},
  author={H{\'e}lo{\"i}se M. Delagr{\`e}verie and Constance Delaugerre and Sharon R. Lewin and Steven G. Deeks and Jonathan Z Li},
  booktitle={Open forum infectious diseases},
  year={2016}
}
In chronic human immunodeficiency virus (HIV)-1 infection, long-lived latently infected cells are the major barrier to virus eradication and functional cure. Several therapeutic strategies to perturb, eliminate, and/or control this reservoir are now being pursued in the clinic. These strategies include latency reversal agents (LRAs) designed to reactivate HIV-1 ribonucleic acid transcription and virus production and a variety of immune-modifying drugs designed to reverse latency, block… CONTINUE READING
Tweets
This paper has been referenced on Twitter 2 times. VIEW TWEETS

Tables and Topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 22 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 98 REFERENCES

Treatment with a TLR7 agonist induces transient viremia in SIV-infected ART-suppressed monkeys

  • JB Whitney, SY Lim, E Christa
  • Abstract 108. In: Conference on Retroviruses and…
  • 2015
Highly Influential
16 Excerpts

- induced human CD 8 ( + ) T cells through conserved subdominant Pol epitopes

  • JM Jacobson, JP Routy, S Welles
  • 2016

Similar Papers

Loading similar papers…